Pfizer Sings Lyrica's Praises In Beating Earnings Guidance
This article was originally published in The Pink Sheet Daily
Company beats recent lowered earnings guidance as a result of strong performance in its human health division as well as faster-than-anticipated cost savings from restructuring program.
You may also be interested in...
Firm projects 2010 annual sales of $2 bil. for the inhaled insulin and $1.5 bil. for the oncologic.
Pregabalin gestational period encompassed approval of three indications, DEA scheduling and production of packaging.
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter